WO2022005175A1 - Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 - Google Patents
Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 Download PDFInfo
- Publication number
- WO2022005175A1 WO2022005175A1 PCT/KR2021/008200 KR2021008200W WO2022005175A1 WO 2022005175 A1 WO2022005175 A1 WO 2022005175A1 KR 2021008200 W KR2021008200 W KR 2021008200W WO 2022005175 A1 WO2022005175 A1 WO 2022005175A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- preparing
- pi3k inhibitor
- reacting
- Prior art date
Links
- 0 CC(C=C)C([C@](Cc1ccccc1)C1C)=Cc(cccc2*)c2C1=C Chemical compound CC(C=C)C([C@](Cc1ccccc1)C1C)=Cc(cccc2*)c2C1=C 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a process for the preparation of compounds as PI3K inhibitors and to intermediate compounds for their preparation.
- Phosphatidylinositol 3-kinase (PI3 kinase; PI3K) is a lipid kinase that phosphorylates lipid molecules instead of proteins, cell survival, signal transduction, control of membrane trafficking plays an important role, etc. Problems with these regulation lead to cancer, inflammatory diseases, and autoimmune diseases.
- PI3K inhibitors can be usefully used in the treatment of cancer, autoimmune diseases, respiratory diseases, and the like. Therefore, simplifying the process in the preparation of compounds as PI3K inhibitors has emerged as an important problem.
- An object of the present invention is to provide a novel method for preparing a compound as a PI3K inhibitor that can simplify the process.
- An object of the present invention is to provide a method for preparing an intermediate compound for the preparation of a compound as a PI3K inhibitor that can simplify the process.
- An object of the present invention is to provide an intermediate compound for the preparation of a compound as a PI3K inhibitor that can simplify the process.
- the present invention provides a method for preparing a compound of formula (7).
- the method for preparing the compound of Formula 7 includes:
- X 1 , X 2 , and X 4 are each independently a halogen atom.
- the X 1 , X 2 and X 4 may be the same as or different from each other.
- X 1 , X 2 and X 4 may each independently be F, Cl, Br or I. More specifically, the X 1 , X 2 and X 4 may each independently be Br or Cl.
- X 1 , X 2 and X 4 may all be Cl.
- the X 1 and X 4 may be Cl.
- any one of R 1 and R 2 is a hydrogen atom and the other is dimethylamine.
- the method for preparing the compound of Chemical Formula 7 may further include (S1-1) preparing the compound of Chemical Formula 4 by halogenating the compound of Chemical Formula 3.
- X 1 and X 2 may be the same as defined in Formulas 4 to 7 above.
- the method for preparing the compound of Formula 7 may further include (S1-2) reacting the compound of Formula 1 with the compound of Formula 2 to prepare the compound of Formula 3 above.
- X 1 and X 2 may each independently be the same as defined in Formulas 4 to 7 above.
- X 3 may be a halogen atom.
- the halogen atom may be any one selected from F, Cl, Br, and I.
- it may be any one selected from Cl and Br.
- the method for preparing the compound as a PI3K inhibitor may include the following steps (S1) to (S3).
- the method for preparing the compound as a PI3K inhibitor may further include the following step (S1-1).
- the method for preparing the compound as a PI3K inhibitor may further include the following step (S1-2).
- the method for preparing the compound of Formula 7 according to an embodiment comprises:
- (S3) may include preparing a compound of Formula 7 by cyclizing the compound of Formula 6, and the same contents may be applied to the compounds of Formulas 1 to 7 as long as there is no contradiction.
- (S3) may include preparing a compound of Formula 7 by cyclizing the compound of Formula 6, and the same contents may be applied to the compounds of Formulas 1 to 7 as long as there is no contradiction.
- the step (S1) may be performed in a polar aprotic solvent.
- the solvent may include dimethyl sulfoxide.
- the step (S1) may be performed under basic conditions.
- a basic compound such as ammonium hydroxide may participate in the reaction.
- the step (S1-2) may be performed in a polar aprotic solvent.
- the solvent may include acetonitrile.
- the step (S1-2) may be performed under basic conditions.
- a basic compound may participate in the reaction.
- the basic compound may be, for example, a tertiary amine such as triethylamine.
- the polar aprotic solvent may include at least one of dichloromethane, tetrahydrofuran, ethyl acetate, dimethyl sulfoxide, dimethylformamide, and acetonitrile, but is not limited thereto.
- step (S1-2) the equivalent ratio of the compound of Formula 1 to the compound of Formula 2 and the triethylamine may be 1:1.1:1.5.
- the X 1 and X 2 may be Cl.
- step (S1-2) the compound of Formula 1 and the compound of Formula 2 are added to an organic solvent (eg, a mixed solvent of acetonitrile and triethylamine) for about 1 to 3 hours
- organic solvent eg, a mixed solvent of acetonitrile and triethylamine
- It may include refluxing and stirring, adding purified water after cooling to room temperature and stirring at room temperature, filtering and washing (for example, the washing solvent may be purified water), and drying.
- the step (S1-1) may be a step of reacting the compound of Formula 3 with N-chlorosuccinimide to perform the chlorination reaction.
- the equivalent ratio of the compound of Formula 3 to the N-chlorosuccinimide may be 1:1.13.
- step (S1-1) may be performed in a polar aprotic solvent. More specifically, step (S1-1) may be performed in at least one solvent selected from dichloromethane and acetonitrile.
- the compound of Formula 3 and N-chlorosuccinimide are added to an organic solvent (eg, dichloromethane), refluxed and stirred for about 3 hours, and cooled to room temperature After concentration, re-concentration after adding an organic solvent (eg, acetonitrile), adding acetonitrile and cooling and stirring to about 0° C. or more and 5° C. or less, filtration and washing (the washing solvent is organic A solvent may be used, for example, acetonitrile may be used), and drying.
- an organic solvent eg, dichloromethane
- the step (S1) may include reacting the compound of Formula 4 with ammonium hydroxide (NH 4 OH) to produce a crude product of Formula 5.
- the step (S1) may include purifying the crude product.
- Purifying the crude product may include at least one selected from ethanol, isopropyl alcohol, and acetone as a purification solvent.
- isopropyl alcohol may be used as a purification solvent.
- step (S1) the equivalent ratio of the compound of Formula 4 and ammonium hydroxide (NH 4 OH) may be 1:5 to 1:15.
- the step of generating the crude product in step (S1) is about 3 hours after adding the compound of Formula 4 and the ammonium hydroxide (NH 4 OH) to an organic solvent (eg, dimethyl sulfoxide) Stirring while warming (about 70° C. to 90° C., for example, about 80° C.), stirring at room temperature for about 1 hour to 2 hours (or about 2 hours or more until a solid is formed) and adding purified water at room temperature It may include a step of stirring again, a step of filtration and washing (purified water may be used as the washing solvent), and a step of drying.
- an organic solvent eg, dimethyl sulfoxide
- the step of purifying the crude product in step (S1) includes adding an organic solvent (eg, isopropyl alcohol) to the crude product, refluxing and stirring for about 30 minutes, at room temperature for about 1 hour Stirring for 2 hours to 2 hours, filtering and washing (the washing solvent may be an organic solvent, for example, isopropyl alcohol may be used), and drying.
- an organic solvent eg, isopropyl alcohol
- step (S2) the equivalent ratio of the compound of Formula 5 and the dimethylformamide-dimethylacetal may be 1:2.
- step (S2) the compound of Formula 5 and dimethylformamide-dimethylacetal are refluxed and stirred for about 1 hour in an organic solvent (eg, dichloromethane), cooled to room temperature, and concentrated , after adding an organic solvent (eg, isopropyl alcohol) to reflux and stirring, cooling and stirring to room temperature, filtration and washing (the washing solvent may be an organic solvent, for example, isopropyl alcohol can be used) and drying.
- an organic solvent eg, dichloromethane
- an organic solvent eg, isopropyl alcohol
- the washing solvent may be an organic solvent, for example, isopropyl alcohol can be used
- the cyclization reaction in step (S3) may include reacting the compound of Formula 6 with a base and adding an acid.
- the acid addition step may be performed after the step of reacting the compound of Formula 6 with the base.
- the base may be a tert-butoxide salt.
- the base may be potassium tert-butoxide or sodium tert-butoxide.
- the acid may be an organic acid or an inorganic acid, for example, acetic acid or hydrochloric acid.
- step (S3) the equivalent ratio of the compound of Formula 6 to the base may be 1:1.5.
- the equivalent ratio of the compound of Formula 6 to the acid may be 1:3.
- step (S3) the compound of Formula 6 is added to an organic solvent (eg, a mixed solvent of tetrahydrofuran and acetonitrile) and then cooled and stirred at about -5°C, the base After adding (for example, about 2 to 3 times), cooling and stirring for about 30 minutes to 2 hours after input, purified water is added, acid (eg, acetic acid) is added dropwise to form a solid, then room temperature It may include a step of stirring for about 1 to 2 hours, filtration and washing (for example, purified water may be used as a washing solvent) and drying.
- an organic solvent eg, a mixed solvent of tetrahydrofuran and acetonitrile
- the method for preparing the compound of Formula 7 may further include purifying the crude product of the compound of Formula 7.
- the present invention may provide a method for preparing a compound of formula (6).
- the method for preparing the compound of Formula 6 according to an embodiment may include reacting the compound of Formula 5 with dimethylformamide-dimethylacetal.
- X 1 and X 4 may each independently be a halogen atom.
- any one of R 1 and R 2 may be a hydrogen atom and the other may be dimethylamine.
- the method for preparing the compound of Formula 6 can reduce the steps of the manufacturing process of the compound of Formula 7 and reduce the process time by providing the compound of Formula 6, which is an intermediate compound used in the manufacturing process of the compound of Formula 7 of the present invention.
- the method for preparing the compound of Formula 7 according to an embodiment may include cyclizing the compound of Formula 6 as described above.
- a compound represented by the following Chemical Formula 6 may be provided.
- X 1 and X 4 may each independently be a halogen atom.
- One of R 1 and R 2 may be a hydrogen atom and the other may be dimethylamine.
- the compound represented by Formula 6 may participate as an intermediate compound in the manufacturing process of the compound as a PI3K inhibitor of an embodiment, thereby reducing process steps and process costs.
- the process steps required for the preparation of a compound as a PI3K inhibitor can be reduced, and the PI3K inhibitor can be used without long-term reflux and stirring reactions that take several days or more. It is possible to synthesize the compound as In addition, since the reaction may proceed under mild reaction conditions, risk factors that may occur during synthesis may be remarkably reduced, and the manufacturing process may be easily managed.
- process simplification may be achieved to shorten a process time, reduce process cost, and facilitate process management. Therefore, the method for producing a compound as a PI3K inhibitor according to an embodiment may be suitable for industrial production of the compound as a PI3K inhibitor.
- the method for producing a compound as a PI3K inhibitor of the present invention it is possible to simplify the manufacturing process of the compound as a PI3K inhibitor, thereby reducing the manufacturing step and manufacturing cost.
- the intermediate compound for the preparation of the compound as a PI3K inhibitor according to the present invention can be used in the manufacturing process of the compound as a PI3K inhibitor, thereby reducing manufacturing steps and manufacturing costs. Accordingly, the productivity of the compound as a PI3K inhibitor can be improved.
- Example 1 (S)-4-((1-(4,8-dichloro-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)amino)pyrido[2 ,3-d]pyrimidine-5(8H)-one ⁇ (S)-4-((1-(4,8-dichloro-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl) Synthesis of ethyl)amino)pyrido[2,3-d]pyrimidin-5(8H)-one ⁇
- step (1) To the intermediate compound QHK (6.0 g, 13 mmol) obtained in step (1), dichloromethane (MC) (35 ml) and N-chlorosuccinimide (NCS) (2.0 g, 15 mmol) were added and 3 It was stirred at reflux for hours. After cooling to room temperature (25° C.), the reaction mixture was concentrated under reduced pressure.
- MC dichloromethane
- NCS N-chlorosuccinimide
- DMSO Dimethylsulfoxide
- ammonium hydroxide 48.6ml, 642mmol
- the crude IQNK product (29.8 g) was placed in isopropyl alcohol (300 ml) and stirred under reflux for 10 minutes, then cooled to room temperature and stirred for 2 hours more. The solid was filtered, washed with isopropyl alcohol (75 ml), and then dried with hot air at 40° C. and purified IQNK ((S)-3-(1-((5-acetyl-6-aminopyrimidin-4-yl)amino )ethyl)-4,8-dichloro-2-phenylisoquinolin-1(2H)-one) was obtained. (26.9g, yield 92%)
- isopropyl alcohol was used as a solvent for the purification of the crude product of IQNK in step (3)
- the embodiment is not limited thereto, and it goes without saying that various organic solvents may be used.
- any one or more organic solvents selected from ethanol, isopropyl alcohol, and acetone may be used.
- an isopropyl alcohol solvent can be used.
- Tetrahydrofuran (6ml) was added to the intermediate compound IQVK (1g, 1.9mmol) obtained in step (4), followed by cooling and stirring at -5°C.
- Potassium tert-butoxide (0.32g, 2.9mmol) was added 3 times and stirred by maintaining the temperature at -5°C for 0.5 hours, then purified water (12ml) was added, acetic acid (0.33ml, 5.7mmol) was added, and then 2 hours while stirring at room temperature.
- a compound as a PI3K inhibitor in the method for preparing a compound as a PI3K inhibitor according to an embodiment, can be synthesized in only five steps from steps (1) to (5).
- the process time can be shortened. More specifically, steps (1) to (5) do not have severe reaction conditions requiring reflux and stirring for several days or more.
- the refluxing and stirring steps are included for about 1 to about 5 hours, and the refluxing and stirring steps that take more time are not included. Accordingly, according to the method for preparing the compound as a PI3K inhibitor of one embodiment, the total working days can be shortened by several days or more.
- reaction may proceed under mild reaction conditions. Accordingly, risk factors that may occur during synthesis may be remarkably reduced, and the manufacturing process may be easily managed.
- TFA Trifluoroacetic acid, trifluoroacetic acid
- MsOH Metal Sulfonic Acid, methanesulfonic acid
- the PI3K inhibitor is manufactured by a manufacturing method including steps (S1) to (S5), thereby simplifying the process, thereby reducing manufacturing steps and reducing manufacturing costs.
- manufacturing process control can be facilitated by preparing the PI3K inhibitor under mild reaction conditions.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (16)
- (S1) 화학식 4의 화합물로 화학식 5의 화합물을 제조하는 단계;(S2) 화학식 5의 화합물과 디메틸포름아미드-디메틸아세탈을 반응시켜 화학식 6의 화합물을 제조하는 단계; 및(S3) 화학식 6의 화합물을 고리화 반응시켜 화학식 7의 화합물을 제조하는 단계를 포함하는 화학식 7의 화합물의 제조방법:[화학식 4][화학식 5][화학식 6][화학식 7]상기 화학식 4 내지 화학식 7에서, X1, X2 및 X4는 각각 독립적으로 할로겐 원자이고,상기 화학식 6에서, R1 및 R2 중 어느 하나는 수소 원자이고 나머지 하나는 디메틸아민이다.
- 제1항에 있어서,상기 (S1) 단계는 염기 조건에서 진행되는 것인, 화학식 7의 화합물의 제조방법.
- 제1항에 있어서,상기 (S1) 단계 극성 비양성자성 용매에서 진행되는 것인, 화학식 7의 화합물의 제조방법.
- 제2항에 있어서,상기 (S1-1) 단계는 상기 화학식 3의 화합물을 N-클로로숙신이미드와 반응시켜 염소화 반응시키는 단계인 화학식 7의 화합물의 제조방법.
- 제1항에 있어서,상기 (S1) 단계는 상기 화학식 4의 화합물과 수산화암모늄을 반응시켜 화학식 5의 조생성물을 생성하는 단계를 포함하는 화학식 7의 화합물의 제조방법.
- 제7항에 있어서,상기 (S1) 단계는 상기 조생성물을 정제하는 단계를 포함하는 화학식 7의 화합물의 제조방법.
- 제8항에 있어서,상기 조생성물을 정제하는 단계는 정제 용매로 에탄올, 이소프로필 알코올 및 아세톤 중 선택되는 적어도 하나를 포함하는 화학식 7의 화합물의 제조방법.
- 제8항에 있어서,상기 조생성물을 정제하는 단계는 이소프로필 알코올을 정제 용매로 사용하는 화학식 7의 화합물의 제조방법.
- 제1항에 있어서,상기 (S3) 단계에서 상기 고리화 반응은 상기 화학식 6의 화합물을 염기와 반응시키는 단계 및 산 첨가 단계를 포함하는 화학식 7의 화합물의 제조방법.
- 제11항에 있어서, 상기 염기는 tert-부톡사이드 염인 화학식 7의 화합물의 제조방법.
- 제11항에 있어서, 상기 산은 아세트산 또는 염산인 것인, 화학식 7의 화합물의 제조방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237003095A KR20230034322A (ko) | 2020-06-30 | 2021-06-29 | Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 |
EP21834397.8A EP4174067A1 (en) | 2020-06-30 | 2021-06-29 | Method for preparing compound as pi3k inhibitor and intermediate compound for preparing same |
BR112022026937A BR112022026937A2 (pt) | 2020-06-30 | 2021-06-29 | Método para preparar composto como inibidor de pi3k e composto intermediário para preparar o mesmo |
US18/013,801 US20230295158A1 (en) | 2020-06-30 | 2021-06-29 | Method for preparing compound as pi3k inhibitor and intermediate compound for preparing same |
JP2023524264A JP2023532162A (ja) | 2020-06-30 | 2021-06-29 | Pi3k阻害剤としての化合物の製造方法及びその製造のための中間体化合物 |
CN202180046834.4A CN115968369A (zh) | 2020-06-30 | 2021-06-29 | 作为pi3k抑制剂的化合物的制备方法及用于制备其的中间体化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200080269 | 2020-06-30 | ||
KR10-2020-0080269 | 2020-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022005175A1 true WO2022005175A1 (ko) | 2022-01-06 |
Family
ID=79317626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/008200 WO2022005175A1 (ko) | 2020-06-30 | 2021-06-29 | Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230295158A1 (ko) |
EP (1) | EP4174067A1 (ko) |
JP (1) | JP2023532162A (ko) |
KR (1) | KR20230034322A (ko) |
CN (1) | CN115968369A (ko) |
BR (1) | BR112022026937A2 (ko) |
WO (1) | WO2022005175A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009099801A1 (en) * | 2008-02-01 | 2009-08-13 | Irm Llc | Pyrido [4, 3-d] pyrimidinone derivatives as kinase inhibitors |
WO2011053861A1 (en) * | 2009-10-29 | 2011-05-05 | Genosco | Kinase inhibitors |
KR20160150006A (ko) * | 2015-06-18 | 2016-12-28 | 한국화학연구원 | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
-
2021
- 2021-06-29 WO PCT/KR2021/008200 patent/WO2022005175A1/ko unknown
- 2021-06-29 BR BR112022026937A patent/BR112022026937A2/pt unknown
- 2021-06-29 JP JP2023524264A patent/JP2023532162A/ja active Pending
- 2021-06-29 CN CN202180046834.4A patent/CN115968369A/zh active Pending
- 2021-06-29 US US18/013,801 patent/US20230295158A1/en active Pending
- 2021-06-29 EP EP21834397.8A patent/EP4174067A1/en active Pending
- 2021-06-29 KR KR1020237003095A patent/KR20230034322A/ko unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009099801A1 (en) * | 2008-02-01 | 2009-08-13 | Irm Llc | Pyrido [4, 3-d] pyrimidinone derivatives as kinase inhibitors |
WO2011053861A1 (en) * | 2009-10-29 | 2011-05-05 | Genosco | Kinase inhibitors |
KR20160150006A (ko) * | 2015-06-18 | 2016-12-28 | 한국화학연구원 | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
Non-Patent Citations (2)
Title |
---|
KATO TETSUZO, YUTAKA YAMAMOTO, MASATSUGU KONDO: "Studies on ketene and its derivatives. LIX. ring-closure of 5-acetyl-2,6-dimethyl-4(3H)-pyrimidone", YAKUGAKU ZASSHI, vol. 93, no. 12, 31 December 1973 (1973-12-31), pages 1685 - 1687, XP055884610, DOI: 10.1248/yakushi1947.93.12_1685 * |
KOMKOV A. V.; POTAPOVA T. V.; ZUEV M. I.; BARANIN S. V.; BUBNOV YU. N.: "Synthesis of new trichloromethyl- and alkoxy-substituted pyrido[2,3-]pyrimidine derivatives", RUSSIAN CHEMICAL BULLETIN, SPRINGER US, NEW YORK, vol. 68, no. 2, 1 February 2019 (2019-02-01), New York, pages 365 - 373, XP037051007, ISSN: 1066-5285, DOI: 10.1007/s11172-019-2394-6 * |
Also Published As
Publication number | Publication date |
---|---|
CN115968369A (zh) | 2023-04-14 |
US20230295158A1 (en) | 2023-09-21 |
KR20230034322A (ko) | 2023-03-09 |
JP2023532162A (ja) | 2023-07-26 |
BR112022026937A2 (pt) | 2023-01-24 |
EP4174067A1 (en) | 2023-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018308164B2 (en) | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same | |
AU2018308038B2 (en) | Improved process for preparing aminopyrimidine derivatives | |
WO2017023123A1 (ko) | 크로마논 유도체의 신규한 제조방법 | |
WO2015034293A1 (ko) | 고순도 페메트렉세드 제조를 위한 향상된 중간체 제조 방법 및 이를 사용하여 고순도 페메트렉세드를 제조하는 방법 | |
WO2022244969A1 (ko) | 메틸렌 락톤계 화합물의 제조방법 | |
WO2022005175A1 (ko) | Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 | |
WO2022080812A1 (ko) | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 | |
WO2018084625A1 (en) | Method for preparation of (s)-n1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride | |
WO2011096697A2 (en) | Process for preparing voriconazole by using new intermediates | |
WO2021201574A1 (ko) | Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 | |
WO2011096729A2 (en) | Novel method of preparing secondary amine compound using microflow reactor | |
EP3356372A1 (en) | Novel process for preparing thienopyrimidine compound and intermediates used therein | |
AU2019268945B2 (en) | Novel processes for preparing a diaminopyrimidine derivative or acid addition salt thereof | |
WO2011111971A2 (ko) | (r)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1h)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법 | |
WO2017052122A1 (ko) | 광학활성을 가진 티에닐알라닌의 제조 방법 | |
WO2015060657A1 (en) | A method for preparing an intermediate of iopromide | |
WO2016076573A2 (ko) | 블로난세린의 제조방법 및 그를 위한 중간체 | |
WO2020204647A1 (en) | Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same | |
WO2013180403A1 (en) | Process for preparing gefitinib and an intermediate used for preparing thereof | |
WO2023013974A1 (ko) | Parp 저해제인 루카파립과 그 중간체의 신규한 제조방법 | |
WO2015053576A1 (en) | Method for preparation of 3-alkylthio-2-bromopyridine | |
WO2019045355A1 (ko) | 리바스티그민 파모산염의 제조방법 | |
WO2017090991A1 (ko) | 벤조피란 유도체의 정제방법, 이의 결정형 및 상기 결정형의 제조방법 | |
WO2023013973A1 (ko) | 신규한 루카파립의 제조방법 | |
WO2020085616A1 (ko) | 아픽사반의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21834397 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023524264 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022026937 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112022026937 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221229 |
|
ENP | Entry into the national phase |
Ref document number: 20237003095 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021834397 Country of ref document: EP Effective date: 20230130 |